Skip to main content

Alzheimer's Disease Blood-Based Biomarkers: A Clinical and Laboratory Perspective

Tracking # 20-1263194

Price not reported

There are no ratings for this course

Learn more
CE Broker Reporting Reported automatically
Method Broadcasted Interactive Event
Dates Contact provider

Course overview

This webinar is for laboratorians, clinicians, and other stakeholders interested in learning about Alzheimer's Disease, the new anti-amyloid FDA approved therapies, and the use of blood-based biomarkers in the patient journey, especially their role in diagnosing early-stage Alzheimer's disease. This webinar will offer a clinician's perspective on the importance of these novel diagnostic tools in detecting amyloid pathology in individuals presenting with cognitive impairment and how they can be integrated into clinical practice, as well as a clinical laboratory perspective on Alzheimer's biomarker implementation. This activity is meant to offer insights into the best practices to incorporate blood-based biomarker tests in the standard of care for patients suspected of Alzheimer's disease.

Subject areas

This course counts toward the state boards and subject areas below.

American Board of Clinical Chemistry

Clinical Chemistry Diplomate

1h Category 1

Molecular Diagnostics Diplomate

1h Category 1

Toxicological Chemistry Diplomate

1h Category 1

Florida Board of Clinical Laboratory Personnel

Clinical Laboratory Director

1h General

Clinical Laboratory Supervisor

1h General

Clinical Laboratory Technician

1h General

Clinical Laboratory Technologist

1h General

Public Health Director

1h General

Public Health Supervisor

1h General

Public Health Technologist

1h General

Disclosure statements

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.


The following faculty reported financial relationships:


  • Alicia Algeciras-Schimnich, PhD
  • Honorarium/Expenses: Roche Diagnostics
  • Board/Committee Membership/Advisory Board: Roche Diagnostics, Fujirebio Diagnostics


  • Vijay Ramanan, MD, PhD
  • Grant/Research Support: Eisai, Transposon Therapeutics, Inc.